Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
- Status
- COMPLETED
- Phase
- PHASE3
Related studies linked through entity extraction aliases.